Канал: Biopharma Webinar Series

BIOPHARMACEUTICAL PROCESS DEVELOPMENT – TRENDS/ CHALLENGES/OPPORTUNITIES

BIOPHARMACEUTICAL PROCESS DEVELOPMENT – TRENDS/ CHALLENGES/OPPORTUNITIES

JUST IN TIME RELEASE OF CAR T CELL THERAPIES

JUST IN TIME RELEASE OF CAR T CELL THERAPIES

BIOPHARMACEUTICAL PROCESS MODEL EVOLUTION – ENABLING PROCESS KNOWLEDGE & ADVANCED PROCESS CONTROL

BIOPHARMACEUTICAL PROCESS MODEL EVOLUTION – ENABLING PROCESS KNOWLEDGE & ADVANCED PROCESS CONTROL

ENGINEERING FIRST PRINCIPLES: APPLICATIONS TO PHARMACEUTICAL MANUFACTURING

ENGINEERING FIRST PRINCIPLES: APPLICATIONS TO PHARMACEUTICAL MANUFACTURING

CASE STUDY & EXPERIENCE ON SANOFI’S & SGS’S IMPLEMENTATION OF BPOG’S LEACHABLE RISK ASSESSMENT MODEL

CASE STUDY & EXPERIENCE ON SANOFI’S & SGS’S IMPLEMENTATION OF BPOG’S LEACHABLE RISK ASSESSMENT MODEL

THE JOURNEY TO LEAN IMPLEMENTATION FOR EFFICIENCY INCREASE

THE JOURNEY TO LEAN IMPLEMENTATION FOR EFFICIENCY INCREASE

BEYOND PURELY DATA-DRIVEN APPROACHES FOR EFFICIENT KNOWLEDGE MANAGEMENT IN PROCESS DEVELOPMENT

BEYOND PURELY DATA-DRIVEN APPROACHES FOR EFFICIENT KNOWLEDGE MANAGEMENT IN PROCESS DEVELOPMENT

CHARACTERIZATION OF BIOTHERAPEUTICS

CHARACTERIZATION OF BIOTHERAPEUTICS

DESIGN OF EXPERIMENTS (DOE) FOR DEVELOPMENT OF HIGH THROUGHPUT, FOR ASSESSMENT OF PRODUCT QUALITY

DESIGN OF EXPERIMENTS (DOE) FOR DEVELOPMENT OF HIGH THROUGHPUT, FOR ASSESSMENT OF PRODUCT QUALITY

FROM CONCEPT TO MARKET – UNIQUE APPROACHES IN BIOMANUFACTURING

FROM CONCEPT TO MARKET – UNIQUE APPROACHES IN BIOMANUFACTURING

BIG DATA STRATEGIES FOR CELL THERAPY MANUFACTURING

BIG DATA STRATEGIES FOR CELL THERAPY MANUFACTURING

CASE STUDY & EXPERIENCE ON SANOFI’S & SGS’S IMPLEMENTATION OF BPOG’S LEACHABLE RISK ASSESSMENT MODEL

CASE STUDY & EXPERIENCE ON SANOFI’S & SGS’S IMPLEMENTATION OF BPOG’S LEACHABLE RISK ASSESSMENT MODEL

ALTERNATIVE AND RAPID MICROBIOLOGICAL METHODS: MICROBIOLOGY OF THE 21ST CENTURY

ALTERNATIVE AND RAPID MICROBIOLOGICAL METHODS: MICROBIOLOGY OF THE 21ST CENTURY

THE JOURNEY TO LEAN IMPLEMENTATION FOR EFFICIENCY INCREASE

THE JOURNEY TO LEAN IMPLEMENTATION FOR EFFICIENCY INCREASE

MAPPING FUTURE TECHNOLOGY NEEDS FOR REAL TIME RELEASE TESTING

MAPPING FUTURE TECHNOLOGY NEEDS FOR REAL TIME RELEASE TESTING

DESIGNING PRODUCTION FACILITIES OF THE FUTURE

DESIGNING PRODUCTION FACILITIES OF THE FUTURE

USE OF COMPUTATIONAL MODELLING IN SPECIFICATION SETTING AND ESTABLISHING CONTROL STRATEGY

USE OF COMPUTATIONAL MODELLING IN SPECIFICATION SETTING AND ESTABLISHING CONTROL STRATEGY

INNOVATIONS IN BIOMANUFACTURING PLANTS

INNOVATIONS IN BIOMANUFACTURING PLANTS

CHEMICAL & PHYSICAL TRANSFORMATION MONITORING BY RAMAN & IR SPECTROSCOPIES IN PHARMA DEVELOPMENT

CHEMICAL & PHYSICAL TRANSFORMATION MONITORING BY RAMAN & IR SPECTROSCOPIES IN PHARMA DEVELOPMENT

PHARMACEUTICAL FORENSICS FOR SAFE MANUFACTURING AND SUPPLY

PHARMACEUTICAL FORENSICS FOR SAFE MANUFACTURING AND SUPPLY

PHARMACEUTICAL HOT MELT EXTRUSION A COST EFFECTIVE METHOD TO INCREASE SOLUBILITY

PHARMACEUTICAL HOT MELT EXTRUSION A COST EFFECTIVE METHOD TO INCREASE SOLUBILITY

INNOVATIVE SOLUTIONS FROM INDUSTRY 4.0

INNOVATIVE SOLUTIONS FROM INDUSTRY 4.0

NEW DRUG PRODUCT DEVELOPMENT USING CONTINUOUS MANUFACTURING

NEW DRUG PRODUCT DEVELOPMENT USING CONTINUOUS MANUFACTURING

REGULATORY STRATEGIES AND CASE STUDIES FOR RAPID STERILITY TESTING OF GENE AND CELL THERAPY PRODUCTS

REGULATORY STRATEGIES AND CASE STUDIES FOR RAPID STERILITY TESTING OF GENE AND CELL THERAPY PRODUCTS

VIRAL SAFETY BY DESIGN FOR CELL AND GENE THERAPY PRODUCTS

VIRAL SAFETY BY DESIGN FOR CELL AND GENE THERAPY PRODUCTS

CHARACTERIZATION OF SUBVISIBLE PARTICLES IN PROTEIN AND VIRAL VACCINES

CHARACTERIZATION OF SUBVISIBLE PARTICLES IN PROTEIN AND VIRAL VACCINES

DO EXTRACTABLE PROTOCOLS TRULY HELP – AN END USER PERSPECTIVE

DO EXTRACTABLE PROTOCOLS TRULY HELP – AN END USER PERSPECTIVE

HOT MELT EXTRUSIONS AS A COST EFFECTIVE METHOD OF INCREASING SOLUBILITY OF WATER INSOLUBLE API’S

HOT MELT EXTRUSIONS AS A COST EFFECTIVE METHOD OF INCREASING SOLUBILITY OF WATER INSOLUBLE API’S

APPLYING LOW FREQUENCY RAMAN TO QBD IN PHARMACEUTICAL DEVELOPMENT

APPLYING LOW FREQUENCY RAMAN TO QBD IN PHARMACEUTICAL DEVELOPMENT

PDA TECHNICAL REPORT ON LOW ENDOTOXIN RECOVERY: IMPLICATIONS TO THE INDUSTRY

PDA TECHNICAL REPORT ON LOW ENDOTOXIN RECOVERY: IMPLICATIONS TO THE INDUSTRY

ANALYSING COMPLEX DATA IN THE PHARMACEUTICAL INDUSTRY: THE CASE FOR MULTIVARIATE ANALYSIS

ANALYSING COMPLEX DATA IN THE PHARMACEUTICAL INDUSTRY: THE CASE FOR MULTIVARIATE ANALYSIS

CHROMASSETTE®, A MODULAR CHROMATOGRAPHY PLATFORM ENABLING NEXT-GENERATION BIOPROCESS PURIFICATION.

CHROMASSETTE®, A MODULAR CHROMATOGRAPHY PLATFORM ENABLING NEXT-GENERATION BIOPROCESS PURIFICATION.

EXTRACTABLES AND LEACHABLES HAVE BEEN USED INTERCHANGEABLELY FOR TOO LONG. ARE WE STILL CONFUSED?

EXTRACTABLES AND LEACHABLES HAVE BEEN USED INTERCHANGEABLELY FOR TOO LONG. ARE WE STILL CONFUSED?

UNDERSTANDING THE PROPENSITY OF SEQUENCE VARIANTS DURING CELL LINE AND CULTURE PROCESS DEVELOPMENT

UNDERSTANDING THE PROPENSITY OF SEQUENCE VARIANTS DURING CELL LINE AND CULTURE PROCESS DEVELOPMENT

CHALLENGES OF HIGH CONCENTRATION PROTEIN FORMULATIONS DEVELOPMENT MOVING TO HIGH POTENT BISPECIFICS

CHALLENGES OF HIGH CONCENTRATION PROTEIN FORMULATIONS DEVELOPMENT MOVING TO HIGH POTENT BISPECIFICS

INTEGRITY ASSURANCE FOR SINGLE-USE SYSTEMS: END-USER PERSPECTIVE

INTEGRITY ASSURANCE FOR SINGLE-USE SYSTEMS: END-USER PERSPECTIVE

MANAGING BIOLOGICS PROCESS ANALYTICAL TECHNOLOGY IN PFIZER

MANAGING BIOLOGICS PROCESS ANALYTICAL TECHNOLOGY IN PFIZER

BPOG RISK BASED APPROACHES TO USE OF CLOSED SYSTEMS IN RENOVATIONS OF EXISTING API FACILITIES

BPOG RISK BASED APPROACHES TO USE OF CLOSED SYSTEMS IN RENOVATIONS OF EXISTING API FACILITIES

ACHIEVING SEAMLESS SCALE-UP AND TECHNOLOGY TRANSFER – A CASE STUDY IN SINGLE-USE BIOREACTORS

ACHIEVING SEAMLESS SCALE-UP AND TECHNOLOGY TRANSFER – A CASE STUDY IN SINGLE-USE BIOREACTORS

CONTINUOUS MANUFACTURING: BUSINESS CASE DRIVERS AND DEPLOYMENT STRATEGIES

CONTINUOUS MANUFACTURING: BUSINESS CASE DRIVERS AND DEPLOYMENT STRATEGIES

EFFECT OF CELL CULTURE PROCESS CHANGE FROM FED-BATCH TO CONTINUOUS ON PRODUCTIVITY & PRODUCT QUALITY

EFFECT OF CELL CULTURE PROCESS CHANGE FROM FED-BATCH TO CONTINUOUS ON PRODUCTIVITY & PRODUCT QUALITY

QUALITY-BY-DESIGN IN SPRAY DRYING PROCESSES – TRANSFER LAB TO PRODUCTION

QUALITY-BY-DESIGN IN SPRAY DRYING PROCESSES – TRANSFER LAB TO PRODUCTION

HOST CELL PROTEIN CHARACTERISATION AND MASS SPECTROMETRY STRATEGIES

HOST CELL PROTEIN CHARACTERISATION AND MASS SPECTROMETRY STRATEGIES

RAW MATERIAL LOT VARIABILITY CHALLENGES DURING MANUFACTURING OF BIOSIMILARS MAB

RAW MATERIAL LOT VARIABILITY CHALLENGES DURING MANUFACTURING OF BIOSIMILARS MAB

USING IN-VITRO DISSOLUTION TO SUPPORT POST APPROVAL CHANGES GLOBAL REGULATORY EXPECTATIONS

USING IN-VITRO DISSOLUTION TO SUPPORT POST APPROVAL CHANGES GLOBAL REGULATORY EXPECTATIONS

SINGLE USE MANUFACTURING – PREPARING FOR COMMERCIAL PRODUCTION

SINGLE USE MANUFACTURING – PREPARING FOR COMMERCIAL PRODUCTION

EXTRACTABLES FROM SINGLE-USE BIOREACTORS/BAGS AND IMPACT ON CELL CULTURE PERFORMANCE

EXTRACTABLES FROM SINGLE-USE BIOREACTORS/BAGS AND IMPACT ON CELL CULTURE PERFORMANCE

CHALLENGES FACED BY THE END USERS DURING THE QUALIFICATION OF SINGLE USE SYSTEM

CHALLENGES FACED BY THE END USERS DURING THE QUALIFICATION OF SINGLE USE SYSTEM

OVERCOMING DOWNSTREAM BOTTLENECKS IN THE UPSCALING PROCESS

OVERCOMING DOWNSTREAM BOTTLENECKS IN THE UPSCALING PROCESS

CONTROLLING VARIABILITY TO INCREASE ACCURACY IN THE BET ASSAY

CONTROLLING VARIABILITY TO INCREASE ACCURACY IN THE BET ASSAY

MAKING CONTINUOUS PROCESSING A REALITY IN THE PHARMACEUTICAL INDUSTRY

MAKING CONTINUOUS PROCESSING A REALITY IN THE PHARMACEUTICAL INDUSTRY

EXTRACTABLES AND LEACHABLES TESTING USING A QUALITY RISK MANAGEMENT APPROACH

EXTRACTABLES AND LEACHABLES TESTING USING A QUALITY RISK MANAGEMENT APPROACH

EVOLVE MANUFACTURING PROCESSES BY IMPLEMENTING DISRUPTIVE TECHNOLOGIES

EVOLVE MANUFACTURING PROCESSES BY IMPLEMENTING DISRUPTIVE TECHNOLOGIES

REDUCING MICROBIOLOGICAL RISK AND USING QUALITY TOOLS IN THE PHARMACEUTICAL INDUSTRY

REDUCING MICROBIOLOGICAL RISK AND USING QUALITY TOOLS IN THE PHARMACEUTICAL INDUSTRY

EFFICIENCY BY DESIGN – CASE STUDY FOR A HYBRID CLINICAL MANUFACTURING FACILITY

EFFICIENCY BY DESIGN – CASE STUDY FOR A HYBRID CLINICAL MANUFACTURING FACILITY

MIXED MODE CHROMATOGRAPHY IN PURIFYING BIOLOGICS – OVERVIEW

MIXED MODE CHROMATOGRAPHY IN PURIFYING BIOLOGICS – OVERVIEW

REGULATORY APPROVAL OF THREE RAPID MICROBIOLOGICAL METHODS FOR MACI PRODUCT RELEASE

REGULATORY APPROVAL OF THREE RAPID MICROBIOLOGICAL METHODS FOR MACI PRODUCT RELEASE

ADVANCES AND CHALLENGES IN VACCINE DEVELOPMENT AND MANUFACTURE

ADVANCES AND CHALLENGES IN VACCINE DEVELOPMENT AND MANUFACTURE

DEVELOPABILITY ASSESSMENT OF THERAPEUTIC PROTEINS – A TOOLBOX FOR TACKLING INCREASING COMPLEXITY

DEVELOPABILITY ASSESSMENT OF THERAPEUTIC PROTEINS – A TOOLBOX FOR TACKLING INCREASING COMPLEXITY

IMPLEMENTING CMC STRATEGIES FOR SCALE-UP OPERATIONS IN BIOLOGICS MANUFACTURING

IMPLEMENTING CMC STRATEGIES FOR SCALE-UP OPERATIONS IN BIOLOGICS MANUFACTURING

DEPTH FILTRATION ON DISULFIDE BOND REDUCTION FROM DOWNSTREAM OF MONOCLONAL ANTIBODIES FROM CHO

DEPTH FILTRATION ON DISULFIDE BOND REDUCTION FROM DOWNSTREAM OF MONOCLONAL ANTIBODIES FROM CHO

DSF & FTIR AS COMPLEMENTARY METHODS FOR THE IDENTIFICATION AND CHARACTERIZATION OF VACCINE PRODUCTS

DSF & FTIR AS COMPLEMENTARY METHODS FOR THE IDENTIFICATION AND CHARACTERIZATION OF VACCINE PRODUCTS

ADVANCED PROCESS DEVELOPMENT USING AUTOMATED MICRO BIOREACTORS SHORTENS TIMELINES FOR RAPID SCALE UP

ADVANCED PROCESS DEVELOPMENT USING AUTOMATED MICRO BIOREACTORS SHORTENS TIMELINES FOR RAPID SCALE UP

MATERIAL UNDERSTANDING FOR CONTINUOUS MANUFACTURING OF SOLID DOSAGE FORMS

MATERIAL UNDERSTANDING FOR CONTINUOUS MANUFACTURING OF SOLID DOSAGE FORMS

NEXT GENERATION PROCESSES: WHAT MODEL WORKS THE BEST IN ASIA?

NEXT GENERATION PROCESSES: WHAT MODEL WORKS THE BEST IN ASIA?

IS INDIA ANYWHERE CLOSER TO IMPLEMENTING CONTINUOUS BIOPROCESSING

IS INDIA ANYWHERE CLOSER TO IMPLEMENTING CONTINUOUS BIOPROCESSING

SUBVISIBLE PARTICLES MATTER, DEVELOPMENTS IN REGULATIONS AND LOW VOLUME METHODS

SUBVISIBLE PARTICLES MATTER, DEVELOPMENTS IN REGULATIONS AND LOW VOLUME METHODS

KEY COMPONENTS FOR THE MANAGEMENT OF SINGLE USE TECHNOLOGIES IN BIOLOGICS MANUFACTURING

KEY COMPONENTS FOR THE MANAGEMENT OF SINGLE USE TECHNOLOGIES IN BIOLOGICS MANUFACTURING

STRATEGIES TO OVERCOME LOW ENDOTOXIN RECOVERY USING THE CONVENTIONAL LAL ASSAY

STRATEGIES TO OVERCOME LOW ENDOTOXIN RECOVERY USING THE CONVENTIONAL LAL ASSAY

PLATFORM TECHNOLOGY DEVELOPMENT FOR BIOSIMILAR UPSCALING

PLATFORM TECHNOLOGY DEVELOPMENT FOR BIOSIMILAR UPSCALING

DEVELOPMENT AND MANUFACTURING OF RECOMBINANT NANOPARTICLE VACCINES

DEVELOPMENT AND MANUFACTURING OF RECOMBINANT NANOPARTICLE VACCINES

MANUFACTURING STRATEGIES FOR BIOSIMILARS: A CASE OF CONTINUOUS CAPTURE

MANUFACTURING STRATEGIES FOR BIOSIMILARS: A CASE OF CONTINUOUS CAPTURE

THE MAIN OPPORTUNITIES AND CHALLENGES IN THE RAPIDLY EVOLVING ASIAN BIOPHARMA MARKETS?

THE MAIN OPPORTUNITIES AND CHALLENGES IN THE RAPIDLY EVOLVING ASIAN BIOPHARMA MARKETS?

USP CHAPTER 1085, “GUIDELINES ON THE ENDOTOXINS TEST”

USP CHAPTER 1085, “GUIDELINES ON THE ENDOTOXINS TEST”

FULLY CONTINUOUS BIOSIMILAR MANUFACTURING FRAMEWORK: A CASE STUDY

FULLY CONTINUOUS BIOSIMILAR MANUFACTURING FRAMEWORK: A CASE STUDY

FINDING THE COMMON ROAD TO QUALITY FOR SINGLE-USE MATERIALS

FINDING THE COMMON ROAD TO QUALITY FOR SINGLE-USE MATERIALS

EXTRACTABLE STUDY DESIGN AND DATA EVALUATION OF POLYMERIC PRODUCT CONTACT MATERIALS

EXTRACTABLE STUDY DESIGN AND DATA EVALUATION OF POLYMERIC PRODUCT CONTACT MATERIALS

CURRENT USP PERSPECTIVES ON A RAPID STERILITY TEST

CURRENT USP PERSPECTIVES ON A RAPID STERILITY TEST

AN INVESTIGATION INTO INTEGRATING OF DISPOSABLE COMPONENTS INTO STAINLESS-STEEL FACILITIES

AN INVESTIGATION INTO INTEGRATING OF DISPOSABLE COMPONENTS INTO STAINLESS-STEEL FACILITIES

IMPLEMENTATION STRATEGIES AND CHALLENGES FOR SINGLE-USE TECHNOLOGIES AT COMMERCIAL SCALE

IMPLEMENTATION STRATEGIES AND CHALLENGES FOR SINGLE-USE TECHNOLOGIES AT COMMERCIAL SCALE

END USER PERSPECTIVE ON SETTING IN-PROCESS ENDOTOXIN LIMITS

END USER PERSPECTIVE ON SETTING IN-PROCESS ENDOTOXIN LIMITS

SINGLE-USE-SYSTEMS: LEACHABLE STUDY DESIGN FOR SINGLE-USE COMPONENTS

SINGLE-USE-SYSTEMS: LEACHABLE STUDY DESIGN FOR SINGLE-USE COMPONENTS

CURRENT PROGRESS IN APPROACHES FOR THE SAFETY ASSESSMENT OF EXTRACTABLES AND LEACHABLES.

CURRENT PROGRESS IN APPROACHES FOR THE SAFETY ASSESSMENT OF EXTRACTABLES AND LEACHABLES.

STERILE PRODUCTS MANUFACTURING – PREPARED FOR THE FUTURE?

STERILE PRODUCTS MANUFACTURING – PREPARED FOR THE FUTURE?

ENABLING COMPREHENSIVE DATA ANALYTICS & PROCESS MONITORING IN BIOMANUFACTURING – KEY SUCCESS FACTORS

ENABLING COMPREHENSIVE DATA ANALYTICS & PROCESS MONITORING IN BIOMANUFACTURING – KEY SUCCESS FACTORS

DISPOSABLES – SUITABILITY AND PROCESS ECONOMY IN BIOPHARMACEUTICAL MANUFACTURING – A REALITY CHECK.

DISPOSABLES – SUITABILITY AND PROCESS ECONOMY IN BIOPHARMACEUTICAL MANUFACTURING – A REALITY CHECK.

DO EXTRACTABLE PROTOCOLS TRULY HELP – AN END USER PERSPECTIVE

DO EXTRACTABLE PROTOCOLS TRULY HELP – AN END USER PERSPECTIVE

ENABLING COMPREHENSIVE DATA ANALYTICS & PROCESS MONITORING IN BIOMANUFACTURING – KEY SUCCESS FACTORS

ENABLING COMPREHENSIVE DATA ANALYTICS & PROCESS MONITORING IN BIOMANUFACTURING – KEY SUCCESS FACTORS

CURRENT AND FUTURE APPLICATIONS OF NEAR-INFRARED IN PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY

CURRENT AND FUTURE APPLICATIONS OF NEAR-INFRARED IN PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY

REAL TIME RELEASE TESTING DISSOLUTION PREDICTION OF TABLETS MADE USING CONTINUOUS DIRECT COMPRESSION

REAL TIME RELEASE TESTING DISSOLUTION PREDICTION OF TABLETS MADE USING CONTINUOUS DIRECT COMPRESSION

CAN THE NEW GENERATION OF PERFUSION TECHNOLOGY COMPETE OR REPLACE THE PREFERRED FED-BATCH?

CAN THE NEW GENERATION OF PERFUSION TECHNOLOGY COMPETE OR REPLACE THE PREFERRED FED-BATCH?

SU & STAINLESS STEEL BIOREACTORS: QUALITY FACTORS FOR CONSIDERATION WHEN SELECTING A SUITABLE SYSTEM

SU & STAINLESS STEEL BIOREACTORS: QUALITY FACTORS FOR CONSIDERATION WHEN SELECTING A SUITABLE SYSTEM

CHARACTERISATION OF HOST-CELL PROTEINS USING MASS SPECTROMETRY ENABLES PURIFICATION OPTIMISATION

CHARACTERISATION OF HOST-CELL PROTEINS USING MASS SPECTROMETRY ENABLES PURIFICATION OPTIMISATION

MANUFACTURING: FLEXIBILITY & SUSTAINABILITY THROUGH SMALL FOOTPRINT, MODULAR EQUIPMENT TRAINS

MANUFACTURING: FLEXIBILITY & SUSTAINABILITY THROUGH SMALL FOOTPRINT, MODULAR EQUIPMENT TRAINS

ADVANCES IN MASS SPECTROMETRY FOR THE ANALYSIS AND BIOANALYSIS OF ANTIBODY DRUG CONJUGATES

ADVANCES IN MASS SPECTROMETRY FOR THE ANALYSIS AND BIOANALYSIS OF ANTIBODY DRUG CONJUGATES

NEW PARADIGM OF BUILDING QUALITY DURING MANUFACTURE – CHALLENGES WITH BIOLOGICAL PRODUCTS

NEW PARADIGM OF BUILDING QUALITY DURING MANUFACTURE – CHALLENGES WITH BIOLOGICAL PRODUCTS

MODERNIZING BIOPHARMACEUTICAL MANUFACTURING: FROM BATCH TO CONTINUOUS PRODUCTION

MODERNIZING BIOPHARMACEUTICAL MANUFACTURING: FROM BATCH TO CONTINUOUS PRODUCTION

A LEAN MANUFACTURING: IMPLEMENTING SINGLE-USE PROCESS ANALYTICAL TECHNOLOGIES TOOLS AT SEED STAGE

A LEAN MANUFACTURING: IMPLEMENTING SINGLE-USE PROCESS ANALYTICAL TECHNOLOGIES TOOLS AT SEED STAGE

DEVELOPING PRACTICAL SINGLE-USE PROCESSES FOR NEW VACCINE FORMULATIONS

DEVELOPING PRACTICAL SINGLE-USE PROCESSES FOR NEW VACCINE FORMULATIONS

SINGLE USE SYSTEMS IN BIOLOGICS MANUFACTURING AND THEIR IMPACT ON OPERATIONAL TECHNOLOGY

SINGLE USE SYSTEMS IN BIOLOGICS MANUFACTURING AND THEIR IMPACT ON OPERATIONAL TECHNOLOGY

ANALYTICAL STRATEGIES FOR COMPARABILITY IN BIOPROCESS DEVELOPMENT

ANALYTICAL STRATEGIES FOR COMPARABILITY IN BIOPROCESS DEVELOPMENT

Subvisible Particle Identification & Characterisation by Multi Technique Methods

Subvisible Particle Identification & Characterisation by Multi Technique Methods